United States Health

Evaxion (NASDAQ:EVAX) reported sustained clinical responses after three years in its phase 2 melanoma vaccine trial, with no tumor progression among six patients followed.

Tiziana Life Sciences (NASDAQ:TLSA) announced on October 16, 2026, that the final patient began dosing in its Phase 2 intranasal foralumab trial for early or mild Alzheimer’s disease.

Biomerica (NASDAQ:BMRA) reported a fiscal first-quarter 2027 net loss of $1.232 million, or $0.37 per share, as revenue declined 8% to $1.265 million.

Organon (NYSE:OGN) announced interim six-year Phase 3 results for its licensed hormone-free MIUDELLA contraceptive device, reporting a cumulative Pearl Index of 0.93.

Regeneron Pharmaceuticals (NASDAQ:REGN) announced a positive European regulatory recommendation allowing Libtayo dosing every six weeks across six approved cancer indications, subject to final authorization.

Fractyl Health (NASDAQ:GUTS) reported that its Revita procedure met a six-month co-primary endpoint in the 308-patient REMAIN-1 study, showing improved weight maintenance after GLP-1 treatment discontinuation.

Ionis Pharmaceuticals (NASDAQ:IONS) announced that European regulators recommended expanding TRYNGOLZA's indication to adults with severe hypertriglyceridemia and fasting triglycerides of at least 880 mg/dL.

Omeros (NASDAQ:OMER) said Europe's drug review committee maintained its negative opinion on narsoplimab for TA-TMA after re-examination, despite the treatment receiving U.S. approval in December 2025.

DataMeds AI (NASDAQ:MEDS) outlined plans on October 16, 2026, for its three Corexa Health divisions following an FDA proposal that could ease compounding restrictions on six peptides.

MiniMed (NASDAQ:MMED) completed its separation from Medtronic (NYSE:MDT) today, marking its first official day as an independent company.

Adlai Nortye (NASDAQ:ANL) signed two supply agreements with Lilly and Merck KGaA to evaluate AN4035 alongside cetuximab.

Aquestive Therapeutics (NASDAQ:AQST) received FDA acceptance for its Anaphylm resubmission with a March 16, 2027 action date.